CRSP: A Catalyst-Driven Long Trade Ahead of Multiple Clinical Readouts
CRISPR Therapeutics ($CRSP) is priced like a growth story with a $4.8B market cap while the market waits on several clinical readouts and label expansion that could re-rate the shares. This trade idea lays out a long bias with an entry at $49.90, a stop at $40.00 and a $85.00 target tied to positive Phase 2/Phase 1 data and commercial progress.